WO2013147649A3 - Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases - Google Patents

Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases Download PDF

Info

Publication number
WO2013147649A3
WO2013147649A3 PCT/RU2013/000243 RU2013000243W WO2013147649A3 WO 2013147649 A3 WO2013147649 A3 WO 2013147649A3 RU 2013000243 W RU2013000243 W RU 2013000243W WO 2013147649 A3 WO2013147649 A3 WO 2013147649A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
treatment
ikk
pi3k
akt
Prior art date
Application number
PCT/RU2013/000243
Other languages
French (fr)
Russian (ru)
Other versions
WO2013147649A2 (en
Inventor
Петр Олегович ФЕДИЧЕВ
Андрей Александрович ВИННИК
Original Assignee
ХОЛИН, Максим Николаевич
НЕСТЕРУК, Владимир Викторович
Открытое Акционерное Общество "Валента Фармацевтика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ХОЛИН, Максим Николаевич, НЕСТЕРУК, Владимир Викторович, Открытое Акционерное Общество "Валента Фармацевтика" filed Critical ХОЛИН, Максим Николаевич
Publication of WO2013147649A2 publication Critical patent/WO2013147649A2/en
Publication of WO2013147649A3 publication Critical patent/WO2013147649A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to inhibitors of the PI3K/AKT/IKK/NF-kB signalling pathway, to analogues thereof and to pharmaceutically acceptable salts thereof, and also to pharmaceutical compositions containing said inhibitors for the prophylaxis and treatment of viral diseases. The invention is linked to methods for the prophylaxis and treatment of viral diseases using inhibitors of the PI3K/AKT/IKK/NF-kB signalling pathway, to analogues thereof, and to pharmaceutically acceptable salts thereof, and also to pharmaceutical compositions containing said inhibitors for the treatment of viral diseases and for the production of drugs.
PCT/RU2013/000243 2012-03-29 2013-03-25 Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases WO2013147649A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012112128/15A RU2012112128A (en) 2012-03-29 2012-03-29 PI3K / AKT / IKK / NF-kB SIGNAL PATH INHIBITORS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND THEIR COMPOSITIONS FOR PREVENTION AND TREATMENT OF VIRAL DISEASES
RU2012112128 2012-03-29

Publications (2)

Publication Number Publication Date
WO2013147649A2 WO2013147649A2 (en) 2013-10-03
WO2013147649A3 true WO2013147649A3 (en) 2013-12-05

Family

ID=49261364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2013/000243 WO2013147649A2 (en) 2012-03-29 2013-03-25 Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases

Country Status (2)

Country Link
RU (1) RU2012112128A (en)
WO (1) WO2013147649A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431437B (en) 2013-07-02 2020-03-10 理森制药股份公司 PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors
RU2574007C2 (en) * 2013-10-16 2016-01-27 Олег Иванович Киселев Injection solution for treating viral diseases specified in h1n1, h3n2, h5n1 influenza, tick-borne encephalitis and west nile fever
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
WO2016069854A1 (en) * 2014-10-30 2016-05-06 Virginia Commonwealth University Enhancing the anti-tumor, anti-viral, and anti-protozoan effects of 2-amino-n-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl] phenyl]acetamide (osu-03012) and other pharmaceutical drugs
US11000491B2 (en) 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
CN110859839B (en) * 2018-08-27 2023-04-18 中国人民解放军军事科学院军事医学研究院 Application of thiazolidinedione compound in preparation of anti-adenovirus medicament
CN111269231B (en) * 2018-12-04 2023-06-09 安徽中科拓苒药物科学研究有限公司 Selective PI3K delta inhibitor and application thereof
CN111793113B (en) * 2019-04-07 2022-08-05 首都医科大学 Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK
EP4105216A4 (en) * 2020-02-13 2024-02-28 Genfleet Therapeutics (Shanghai) Inc. Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof
TW202220661A (en) * 2020-08-07 2022-06-01 德商柏林化學股份公司 Improved pharmaceutical formulations comprising pi3k inhibitors
WO2022106579A1 (en) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for treating a disease associated with macrophage senescence
CN113045559B (en) * 2021-03-15 2022-05-20 贵州医科大学 Diaryl urea PI3K alpha/mTOR double-target inhibitor and pharmaceutical composition and application thereof
CN113332290B (en) * 2021-05-11 2023-09-15 湖北工业大学 Application of Voxtalisib compound in preparation of anti-EV 71 virus drugs
WO2023170187A1 (en) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025419A1 (en) * 2004-06-25 2006-02-02 Ann Richmond Imidazoquinoxaline compound for the treatment of melanoma
WO2006109196A2 (en) * 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025419A1 (en) * 2004-06-25 2006-02-02 Ann Richmond Imidazoquinoxaline compound for the treatment of melanoma
WO2006109196A2 (en) * 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"«RLS-2004»", RLS, ENTSIKLOPEDIA LEKARSTV, M, vol. 11, 2004, pages 274 - 275 *
"«RLS-2008»", RLS, ENTSIKLOPEDIA LEKARSTV, M., vol. 16, 2007, pages 615, 844 - 845, 852-853 *
"«RLS-2008»", RLS, ENTSIKLOPEDIA LEKARSTV, M., vol. 16, 2007, pages 652 - 655 *
HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, 2006, pages 93 - 98 *
MARJUKI N. ET AL.: "Influenza A virus-induced early activation of ERK and P13K mediated V-ATPase-dependent intracellular pH change required for fusion.", CELL MICROBIOL., vol. 13, no. 4, April 2011 (2011-04-01), pages 587 - 601 *
YEUNG AW ET AL.: "Flavivirus infection induces indoleamine 2,3- dioxygenase in human monocyte-derived macrophages via tumor necrosis factor and NF-kB.", J.LEUKOC.BIOL., vol. 91, no. 4, 2012, pages 657 - 666 *

Also Published As

Publication number Publication date
RU2012112128A (en) 2013-10-10
WO2013147649A2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
WO2013147649A3 (en) Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
WO2011086531A3 (en) New anti-malarial agents
IN2014DN09434A (en)
MY169987A (en) Selective pi3k delta inhibitors
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2012174158A3 (en) Administration of benzodiazepine
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
IN2014MN01622A (en)
MX2014002395A (en) Novel rock kinase inhibitors.
MX2016003522A (en) Quinazoline derivatives and their use as dna methyltransferase inhibitors.
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
IL250201A0 (en) Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
WO2012149295A3 (en) Methods of administering anatabine to treat autism spectrum disorders and seizure disorders
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13769558

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC , EPO FORM 1205N DATED 30.3.2015

122 Ep: pct application non-entry in european phase

Ref document number: 13769558

Country of ref document: EP

Kind code of ref document: A2